ArticleFrontiers in cardiovascular medicine2025
Impact of β-blockers on mortality in critically Ill patients with type 2 myocardial infarction: insights from a retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 myocardial infarction (T2MI) is common in critically ill patients, is associated with high mortality. However, the effect of β-blocker therapy on mortality remains uncertain. Objective: To evaluate the impact of β-blockers on short-term and long-term mortality in intensive care unit (ICU) patients with T2MI. Methods: This retrospective study analyzed 1,636 T2MI patients from the MIMIC-IV database. Propensity score matching (PSM) adjusted for confounders, resulting in 489 matched pairs. Mortality risks were analyzed using multivariable regression models, with subgroup and sensitivity analyses validating findings. Results: Before PSM, in-hospital, 30-day, and 1-year mortality rates were 13.3%, 17.2%, and 34.1%. Kaplan-Meier survival analysis demonstrated significantly higher survival probability in the β-blocker group (log-rank test, Conclusions: β-blockers significantly reduce mortality in critically ill T2MI patients, supporting their use as a key treatment strategy for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.